Literature DB >> 30926524

Post-transcriptional markers associated with clinical complications in Type 1 and Type 2 diabetes mellitus.

Juliana Doblas Massaro1, Claudia Danella Polli2, Matheus Costa E Silva2, Cinthia Caroline Alves2, Geraldo Aleixo Passos3, Elza Tiemi Sakamoto-Hojo4, Wallace Rodrigues de Holanda Miranda5, Nathalia Joanne Bispo Cezar2, Diane Meyre Rassi2, Felipe Crispim6, Sergio Atala Dib6, Maria Cristina Foss-Freitas5, Daniel Guariz Pinheiro7, Eduardo Antônio Donadi8.   

Abstract

The delayed diagnosis and the inadequate treatment of diabetes increase the risk of chronic complications. The study of regulatory molecules such as miRNAs can provide expression profiles of diabetes and diabetes complications. We evaluated the mononuclear cell miRNA profiles of 63 Type 1 and Type 2 diabetes patients presenting or not microvascular complications, and 40 healthy controls, using massive parallel sequencing. Gene targets, enriched pathways, dendograms and miRNA-mRNA networks were performed for the differentially expressed miRNAs. Six more relevant miRNAs were validated by RT-qPCR and data mining analysis. MiRNAs associated with specific complications included: i) neuropathy (miR-873-5p, miR-125a-5p, miR-145-3p and miR-99b-5p); ii) nephropathy (miR-1249-3p, miR-193a-5p, miR-409-5p, miR-1271-5p, miR-501-3p, miR-148b-3p and miR-9-5p); and iii) retinopathy (miR-143-3p, miR-1271-5p, miR-409-5p and miR-199a-5p). These miRNAs mainly targeted gene families and specific genes associated with advanced glycation end products and their receptors. Sets of miRNAs were also defined as potential targets for diabetes/diabetes complication pathogenesis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Diabetes microvascular complications; Type 1 diabetes; Type 2 diabetes; miRNome analysis

Mesh:

Substances:

Year:  2019        PMID: 30926524     DOI: 10.1016/j.mce.2019.03.008

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  16 in total

1.  Effect of Shuangdan Mingmu Capsule on Diabetic Retinopathy in Rats via Regulation of miRNAs.

Authors:  Xiang Li; Yijing Yang; Yan Song; Fujiao Nie; Chaojun Fu; Yuhui Qin
Journal:  Diabetes Metab Syndr Obes       Date:  2022-10-19       Impact factor: 3.249

2.  Long non-coding RNA cancer susceptibility candidate 2 (CASC2) alleviates the high glucose-induced injury of CIHP-1 cells via regulating miR-9-5p/PPARγ axis in diabetes nephropathy.

Authors:  Feng Li; Bo Dai; Xiquan Ni
Journal:  Diabetol Metab Syndr       Date:  2020-08-06       Impact factor: 3.320

3.  MicroRNA-409-5p promotes retinal neovascularization in diabetic retinopathy.

Authors:  Ying Wang; Wenwen Lin; Jianghua Ju
Journal:  Cell Cycle       Date:  2020-04-15       Impact factor: 4.534

4.  microRNA-143-3p contributes to inflammatory reactions by targeting FOSL2 in PBMCs from patients with autoimmune diabetes mellitus.

Authors:  Shan Pan; Mengyu Li; Haibo Yu; Zhiguo Xie; Xia Li; Xianlan Duan; Gan Huang; Zhiguang Zhou
Journal:  Acta Diabetol       Date:  2020-08-20       Impact factor: 4.280

5.  MicroRNA predicts cognitive performance in healthy older adults.

Authors:  Joseph M Gullett; Zhaoyi Chen; Andrew O'Shea; Maisha Akbar; Jiang Bian; Asha Rani; Eric C Porges; Thomas C Foster; Adam J Woods; Francois Modave; Ronald A Cohen
Journal:  Neurobiol Aging       Date:  2020-08-03       Impact factor: 4.673

6.  Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta; Jan Sirc
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

7.  Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study.

Authors:  Valborg Gudmundsdottir; Helle Krogh Pedersen; Gianluca Mazzoni; Kristine H Allin; Anna Artati; Joline W Beulens; Karina Banasik; Caroline Brorsson; Henna Cederberg; Elizaveta Chabanova; Federico De Masi; Petra J Elders; Ian Forgie; Giuseppe N Giordano; Harald Grallert; Ramneek Gupta; Mark Haid; Torben Hansen; Tue H Hansen; Andrew T Hattersley; Alison Heggie; Mun-Gwan Hong; Angus G Jones; Robert Koivula; Tarja Kokkola; Markku Laakso; Peter Løngreen; Anubha Mahajan; Andrea Mari; Timothy J McDonald; Donna McEvoy; Petra B Musholt; Imre Pavo; Cornelia Prehn; Hartmut Ruetten; Martin Ridderstråle; Femke Rutters; Sapna Sharma; Roderick C Slieker; Ali Syed; Juan Fernandez Tajes; Cecilia Engel Thomas; Henrik S Thomsen; Jagadish Vangipurapu; Henrik Vestergaard; Ana Viñuela; Agata Wesolowska-Andersen; Mark Walker; Jerzy Adamski; Jochen M Schwenk; Mark I McCarthy; Ewan Pearson; Emmanouil Dermitzakis; Paul W Franks; Oluf Pedersen; Søren Brunak
Journal:  Genome Med       Date:  2020-12-01       Impact factor: 11.117

Review 8.  Dysbiosis in the Development of Type I Diabetes and Associated Complications: From Mechanisms to Targeted Gut Microbes Manipulation Therapies.

Authors:  Gratiela Gradisteanu Pircalabioru; Nicolae Corcionivoschi; Ozan Gundogdu; Mariana-Carmen Chifiriuc; Luminita Gabriela Marutescu; Bogdan Ispas; Octavian Savu
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

9.  Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

Review 10.  Emerging Roles of microRNAs as Biomarkers and Therapeutic Targets for Diabetic Neuropathy.

Authors:  Baoyan Fan; Michael Chopp; Zheng Gang Zhang; Xian Shuang Liu
Journal:  Front Neurol       Date:  2020-10-22       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.